bluebird bio Pauses During 2017 Data Blitz

Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and earnings are essentially meaningless at this point for the biotech company.

For the record, Bluebird lost $70.9 million, which was more than the $58.8 million it lost in the year-ago quarter, mostly because of increased research and development expenses as its pipeline treatment candidates advance. Fortunately, after raising additional cash, Bluebird has a nice cushion, even at the higher burn rate.

Image source: Getty Images.

Source: Fool.com